Adrenoleukodystrophy Drugs Market
1 Adrenoleukodystrophy Drugs Market Overview
1.1 Product Overview and Scope of Adrenoleukodystrophy Drugs
1.2 Adrenoleukodystrophy Drugs Segment by Type
1.2.1 Global Adrenoleukodystrophy Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Hormone Replacement
1.2.3 Transplant
1.2.4 Others
1.3 Adrenoleukodystrophy Drugs Segment by Application
1.3.1 Global Adrenoleukodystrophy Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Childhood Cerebral ALD
1.3.3 Adrenomyeloneuropathy (AMN)
1.3.4 Addison-only
1.3.5 Others
1.4 Global Adrenoleukodystrophy Drugs Market Size Estimates and Forecasts
1.4.1 Global Adrenoleukodystrophy Drugs Revenue 2016-2027
1.4.2 Global Adrenoleukodystrophy Drugs Sales 2016-2027
1.4.3 Adrenoleukodystrophy Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Adrenoleukodystrophy Drugs Market Competition by Manufacturers
2.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Adrenoleukodystrophy Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Adrenoleukodystrophy Drugs Manufacturing Sites, Area Served, Product Type
2.5 Adrenoleukodystrophy Drugs Market Competitive Situation and Trends
2.5.1 Adrenoleukodystrophy Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Adrenoleukodystrophy Drugs Players Market Share by Revenue
2.5.3 Global Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adrenoleukodystrophy Drugs Retrospective Market Scenario by Region
3.1 Global Adrenoleukodystrophy Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Adrenoleukodystrophy Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.3.1 North America Adrenoleukodystrophy Drugs Sales by Country
3.3.2 North America Adrenoleukodystrophy Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.4.1 Europe Adrenoleukodystrophy Drugs Sales by Country
3.4.2 Europe Adrenoleukodystrophy Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Adrenoleukodystrophy Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Adrenoleukodystrophy Drugs Sales by Region
3.5.2 Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.6.1 Latin America Adrenoleukodystrophy Drugs Sales by Country
3.6.2 Latin America Adrenoleukodystrophy Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Adrenoleukodystrophy Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country
3.7.2 Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Adrenoleukodystrophy Drugs Historic Market Analysis by Type
4.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2016-2021)
4.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Adrenoleukodystrophy Drugs Price by Type (2016-2021)
5 Global Adrenoleukodystrophy Drugs Historic Market Analysis by Application
5.1 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2016-2021)
5.2 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Adrenoleukodystrophy Drugs Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Bluebird Bio Inc
6.1.1 Bluebird Bio Inc Corporation Information
6.1.2 Bluebird Bio Inc Description and Business Overview
6.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio
6.1.5 Bluebird Bio Inc Recent Developments/Updates
6.2 NeuroVia, Inc.
6.2.1 NeuroVia, Inc. Corporation Information
6.2.2 NeuroVia, Inc. Description and Business Overview
6.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio
6.2.5 NeuroVia, Inc. Recent Developments/Updates
6.3 Orpheris, Inc.
6.3.1 Orpheris, Inc. Corporation Information
6.3.2 Orpheris, Inc. Description and Business Overview
6.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio
6.3.5 Orpheris, Inc. Recent Developments/Updates
6.4 Minoryx
6.4.1 Minoryx Corporation Information
6.4.2 Minoryx Description and Business Overview
6.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Minoryx Adrenoleukodystrophy Drugs Product Portfolio
6.4.5 Minoryx Recent Developments/Updates
6.5 MedDay Pharmaceuticals
6.5.1 MedDay Pharmaceuticals Corporation Information
6.5.2 MedDay Pharmaceuticals Description and Business Overview
6.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio
6.5.5 MedDay Pharmaceuticals Recent Developments/Updates
7 Adrenoleukodystrophy Drugs Manufacturing Cost Analysis
7.1 Adrenoleukodystrophy Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Adrenoleukodystrophy Drugs
7.4 Adrenoleukodystrophy Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Adrenoleukodystrophy Drugs Distributors List
8.3 Adrenoleukodystrophy Drugs Customers
9 Adrenoleukodystrophy Drugs Market Dynamics
9.1 Adrenoleukodystrophy Drugs Industry Trends
9.2 Adrenoleukodystrophy Drugs Growth Drivers
9.3 Adrenoleukodystrophy Drugs Market Challenges
9.4 Adrenoleukodystrophy Drugs Market Restraints
10 Global Market Forecast
10.1 Adrenoleukodystrophy Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Adrenoleukodystrophy Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Adrenoleukodystrophy Drugs by Type (2022-2027)
10.2 Adrenoleukodystrophy Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Adrenoleukodystrophy Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Adrenoleukodystrophy Drugs by Application (2022-2027)
10.3 Adrenoleukodystrophy Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Adrenoleukodystrophy Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Adrenoleukodystrophy Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Adrenoleukodystrophy Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Adrenoleukodystrophy Drugs Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Adrenoleukodystrophy Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Adrenoleukodystrophy Drugs Covered in This Study
Table 5. Global Adrenoleukodystrophy Drugs Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Adrenoleukodystrophy Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Adrenoleukodystrophy Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Adrenoleukodystrophy Drugs Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Adrenoleukodystrophy Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Adrenoleukodystrophy Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Adrenoleukodystrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Adrenoleukodystrophy Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Adrenoleukodystrophy Drugs Sales by Region (2016-2021) & (K Units)
Table 16. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Adrenoleukodystrophy Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Adrenoleukodystrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 19. North America Adrenoleukodystrophy Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Adrenoleukodystrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Adrenoleukodystrophy Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Adrenoleukodystrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 23. Europe Adrenoleukodystrophy Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Adrenoleukodystrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Adrenoleukodystrophy Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Adrenoleukodystrophy Drugs Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Adrenoleukodystrophy Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Adrenoleukodystrophy Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Adrenoleukodystrophy Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Adrenoleukodystrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Adrenoleukodystrophy Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Adrenoleukodystrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Adrenoleukodystrophy Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Adrenoleukodystrophy Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Adrenoleukodystrophy Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Adrenoleukodystrophy Drugs Sales (K Units) by Type (2016-2021)
Table 39. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Adrenoleukodystrophy Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Adrenoleukodystrophy Drugs Revenue Share by Type (2016-2021)
Table 42. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Type (2016-2021)
Table 43. Global Adrenoleukodystrophy Drugs Sales (K Units) by Application (2016-2021)
Table 44. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Adrenoleukodystrophy Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Adrenoleukodystrophy Drugs Revenue Share by Application (2016-2021)
Table 47. Global Adrenoleukodystrophy Drugs Price (US$/Unit) by Application (2016-2021)
Table 48. Bluebird Bio Inc Corporation Information
Table 49. Bluebird Bio Inc Description and Business Overview
Table 50. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product
Table 52. Bluebird Bio Inc Recent Developments/Updates
Table 53. NeuroVia, Inc. Corporation Information
Table 54. NeuroVia, Inc. Description and Business Overview
Table 55. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product
Table 57. NeuroVia, Inc. Recent Developments/Updates
Table 58. Orpheris, Inc. Corporation Information
Table 59. Orpheris, Inc. Description and Business Overview
Table 60. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Orpheris, Inc. Adrenoleukodystrophy Drugs Product
Table 62. Orpheris, Inc. Recent Developments/Updates
Table 63. Minoryx Corporation Information
Table 64. Minoryx Description and Business Overview
Table 65. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Minoryx Adrenoleukodystrophy Drugs Product
Table 67. Minoryx Recent Developments/Updates
Table 68. MedDay Pharmaceuticals Corporation Information
Table 69. MedDay Pharmaceuticals Description and Business Overview
Table 70. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product
Table 72. MedDay Pharmaceuticals Recent Developments/Updates
Table 73. Production Base and Market Concentration Rate of Raw Material
Table 74. Key Suppliers of Raw Materials
Table 75. Adrenoleukodystrophy Drugs Distributors List
Table 76. Adrenoleukodystrophy Drugs Customers List
Table 77. Adrenoleukodystrophy Drugs Market Trends
Table 78. Adrenoleukodystrophy Drugs Growth Drivers
Table 79. Adrenoleukodystrophy Drugs Market Challenges
Table 80. Adrenoleukodystrophy Drugs Market Restraints
Table 81. Global Adrenoleukodystrophy Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 82. Global Adrenoleukodystrophy Drugs Sales Market Share Forecast by Type (2022-2027)
Table 83. Global Adrenoleukodystrophy Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 84. Global Adrenoleukodystrophy Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 85. Global Adrenoleukodystrophy Drugs Sales Forecast by Application (2022-2027) & (K Units)
Table 86. Global Adrenoleukodystrophy Drugs Sales Market Share Forecast by Application (2022-2027)
Table 87. Global Adrenoleukodystrophy Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 88. Global Adrenoleukodystrophy Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 89. Global Adrenoleukodystrophy Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 90. Global Adrenoleukodystrophy Drugs Sales Market Share Forecast by Region (2022-2027)
Table 91. Global Adrenoleukodystrophy Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 92. Global Adrenoleukodystrophy Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Adrenoleukodystrophy Drugs
Figure 2. Global Adrenoleukodystrophy Drugs Market Share by Type in 2020 & 2027
Figure 3. Hormone Replacement Product Picture
Figure 4. Transplant Product Picture
Figure 5. Others Product Picture
Figure 6. Global Adrenoleukodystrophy Drugs Market Share by Application in 2020 & 2027
Figure 7. Childhood Cerebral ALD
Figure 8. Adrenomyeloneuropathy (AMN)
Figure 9. Addison-only
Figure 10. Others
Figure 11. Global Adrenoleukodystrophy Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Adrenoleukodystrophy Drugs Market Size 2016-2027 (US$ Million)
Figure 13. Global Adrenoleukodystrophy Drugs Sales 2016-2027 (K Units)
Figure 14. Global Adrenoleukodystrophy Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Adrenoleukodystrophy Drugs Sales Share by Manufacturers in 2020
Figure 16. Global Adrenoleukodystrophy Drugs Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Adrenoleukodystrophy Drugs Players: Market Share by Revenue in 2020
Figure 18. Adrenoleukodystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2016-2021)
Figure 20. Global Adrenoleukodystrophy Drugs Sales Market Share by Region in 2020
Figure 21. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2016-2021)
Figure 22. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region in 2020
Figure 23. U.S. Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Philippines Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Vietnam Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Mexico Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Brazil Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Argentina Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Turkey Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Saudi Arabia Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. UAE Adrenoleukodystrophy Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Sales Market Share of Adrenoleukodystrophy Drugs by Type (2016-2021)
Figure 48. Sales Market Share of Adrenoleukodystrophy Drugs by Application (2016-2021)
Figure 49. Sales Market Share of Adrenoleukodystrophy Drugs by Application in 2020
Figure 50. Revenue Share of Adrenoleukodystrophy Drugs by Application (2016-2021)
Figure 51. Revenue Share of Adrenoleukodystrophy Drugs by Application in 2020
Figure 52. Manufacturing Cost Structure of Adrenoleukodystrophy Drugs
Figure 53. Manufacturing Process Analysis of Adrenoleukodystrophy Drugs
Figure 54. Adrenoleukodystrophy Drugs Industrial Chain Analysis
Figure 55. Channels of Distribution
Figure 56. Distributors Profiles
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Industry Market Size
